Increases the rates for the Long-Acting Reversible Contraceptive devices (LARCs). Adds Healthcare Common Procedure Coding System (HCPCS) code J2350 - Ocrelizumab to the physician office and outpatient fee schedule at $57.42 based on the current approved Medicaid State Plan reimbursement methodology at 100% of the January 2020 Medicare Average Sales Price (ASP) Drug Pricing file for physician-administered drugs, immune globulins, vaccines and toxoids
State
Approval Date
Effective Date
File 1 - Approval Document Media